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Abstract 
Hereditary blood coagulation Factor VII (FVII) deficiency is a rare autosomal recessive bleeding disorder resulting 
from variants in the gene encoding FVII (F7). Integration of genetic variation with functional consequences on 
protein function is essential for the interpretation of the pathogenicity of novel variants. Here, we describe an 
integration of previous locus specific databases for F7 into a single curated database with enhanced features. The 
database provides access to in silico analyses that may be useful in the prediction of variant pathogenicity as well as 
cross-species sequence alignments, structural information and functional and clinical severity described for each 
variant where appropriate. The variant data is shared with the F7 LOVD. The updated database now includes 221 
unique variants, representing gene variants identified in 728 individuals. Single nucleotide variants are the most 
common type (88%) with missense representing 74% of these variants. A number of variants are found with 
relatively high minor allele frequencies that are not pathogenic but contribute significantly to the likely pathogenicity 
of co-inherited variants due to their effect on FVII plasma levels. This comprehensive collection of curated 
information significantly aids the assessment of pathogenicity. 
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Introduction 
The initiation of blood coagulation and subsequent wound repair is a fundamental defence mechanism conserved in 
all vertebrates. Exposure of blood coagulation factor (F) VII/VIIa to cells expressing its cellular receptor and cofactor 
tissue factor (TF) is both necessary and sufficient to initiate blood coagulation in vivo, leading to the generation of 
thrombin and a fibrin clot (Figure 1A). 
 
FVII is a zymogen of a vitamin K-dependent serine protease that is synthesized in the liver and circulates in plasma as 
a single-chain molecule (416 amino acids) at a concentration of approximately 0.5µg/mL (10nmol/L). In common 
with the other serine proteases of the coagulation network (FIX, FX, prothrombin and protein C) as well as protein S 
and protein Z, FVII has an N-terminal domain that contains 10 glutamic acid residues that are post-translationally 
modified by the addition of a carboxyl group to the γ-carbon by a vitamin K- dependent carboxylase. This 
γ−carboxyglutamic acid (GLA) domain confers affinity to negatively charged phospholipid membranes such as those 
of activated platelets, promoting the assembly of functional multiprotein complexes on these surfaces. The primary 
translation product of FVII (466 amino acids) contains a pre-pro leader sequence consisting of a secretory leader 
(signal) sequence and a highly conserved (pro) sequence found in other vitamin K-dependent proteins that directs 
the γ−carboxylation. The GLA domain is followed by two epidermal growth factor (EGF)-like domains, the connecting 
or activation peptide, and the serine protease domain (Figure 1B). 
 
FVII is converted to its activated form FVIIa as the result of a single proteolytic cleavage between Arg212 and Ile213 
(all residues are numbered according to Goodeve et al (Goodeve, Reitsma, & McVey, 2011) using Human Genome 
Variation Society (HGVS) nomenclature, numbering the initiation methionine of the reference protein sequence 
(NP_000122.1) as +1), and may differ from legacy numbering +60), producing a disulfide linked two-chain molecule. 
In blood, 4% of the total circulating FVII is in the form of FVIIa that has little functional activity in the absence of its 
cofactor TF. Unlike other members of the trypsin superfamily, the neo N-terminus generated upon activation of FVII 
fails to insert into the activation pocket leading to a non-optimal alignment of the catalytic machinery, rendering the 
FVIIa ‘zymogen like’ with significantly reduced catalytic activity. Binding of FVIIa to TF allosterically corrects this 
defect, transforming FVIIa into a catalytically competent enzyme. In addition, TF ensures optimal orientation and 
positioning of the FVIIa catalytic domain above the membrane for optimal interaction with its substrates, thereby 
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enhancing the proteolytic activity by 106-fold. The substrates of the TF-FVIIa complex are blood coagulation FIX and 
FX. A schematic of TF-FVIIa initiated thrombin generation is shown in Figure 1A. 
 
The FVII gene (F7) is located on chromosome 13 (13q34) and spans 14909 base pairs. F7 lies adjacent to the factor X 
gene (F10), 2118bp apart, suggesting gene duplication during evolution. Three alternative mRNA transcripts have 
been described. The longest reference transcript (NM_000131.4) has 9 exons and encodes the longest isoform 
composed of 466 amino acid residues including the secretory leader (1-20) and propeptide (21-60) required for 
appropriate γ−carboxylation of glutamic acid residues in the N-terminal GLA domain. Transcript NM_019616.4 lacks 
exon 2, which encodes residues 22-43 of the propeptide but encodes an identical mature FVII protein. NM_019616.4 
is the most abundant and physiologically relevant mRNA transcript. Transcript NM_001267554.1 is the shortest 
transcript lacking exons 2, 3 & 4, thus encoding a protein lacking the critically functional GLA and EGF1 domains. 
 
Deficiency of FVII is an autosomal recessive bleeding disorder with a highly variable phenotype that results from 
variants in F7. The clinical heterogeneity ranges from lethal to mild or even asymptomatic forms. In many cases, 
especially from Southern Europe and African countries, the identification of variants associated with an 
asymptomatic clinical phenotype arises from the use of non-human TF as the trigger for functional coagulation 
assays. The use of TF from animal sources or recombinant versions thereof may result in a discrepant in vitro result 
that is inconsistent with FVII activity (FVII:C) assays performed using human TF and the bleeding phenotype of the 
individual concerned (Bolton-Maggs, Hay, Shanks, Mitchell, & McVey, 2007). Whereas in the more common 
inherited bleeding disorders haemophilia A and B there is a good correlation between residual clotting activity and 
the severity of any associated bleeding, in FVII deficiency this relationship is less clear. This might be explained by the 
lack of sensitivity in assays in differentiating between a total absence of FVII:C activity from extremely low levels. 
Most individuals experience mild mucous membrane bleeding, menorrhagia and post-surgical bleeding but more 
significant events such as life threatening central nervous system bleeds are well recognized. Neonatal central 
nervous system bleeds that are often fatal are characteristic of severely affected cases and arise in individuals with 
variants that result in extremely low or undetectable FVII levels. This mirrors the phenotype observed in mice made 
null for F7 by homologous recombination who die either from fatal intra-abdominal haemorrhage in the peri-partum 
period or intracranial haemorrhage before the age of 24 days (Rosen et al., 1997). 
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The first web-based FVII variant database was established in 2001 (McVey, Boswell, Mumford, Kemball-Cook, & 
Tuddenham, 2001), however availability of time and funding impacted the ability to maintain the database as well as 
continuity of access to a stable URL. A locus specific database (LSDB) loses its relevance once it is not maintained and 
updated on a regular basis. Although a replacement F7 variant database (umd.be/F7)(Beroud et al., 2005) was 
developed, the European Association for Haemophilia and Allied Disorders (EAHAD) initiated a Coagulation Factor 
Variant Database Project with the aim of gathering together single gene variant databases involved in clinical 
bleeding disorders that would provide a single web portal (dbs.eahad.org) to LSDBs for genes in haemostasis, 
mirroring the data to Leiden Open Variation Databases (LOVD) thus addressing the concerns of ‘Yet another 
database?’ (den Dunnen, 2018). The first interactive coagulation factor web database was developed for F11 variants 
(Saunders, O'Connell, Lee, Perry, & Perkins, 2005) and the EAHAD databases build on this structure. The LSDBs would 
share a common architecture making navigation of the database(s) easier as well as providing greater support for 
maintenance of the sites. New databases for FVIII (f8-db.eahad.org) and FIX (f9-db.eahad.org) (Rallapalli, Kemball-
Cook, Tuddenham, Gomez, & Perkins, 2013) gene variants have evolved from previously developed single gene 
variant coagulation database projects (Giannelli et al., 1990; Kemball-Cook, Tuddenham, & Wacey, 1998), 
incorporating new data, new analysis tools and a new common database architecture with new interfaces and filters. 
The project aims to improve the quality and quantity of information available to the haemostasis research and 
clinical communities, thereby enabling accurate classification of disease severity in order to make assessments of 
likely pathogenicity. The databases are curated by international experts in the field who are contributing to the 
ClinGen (clinicalgenome.org) initiative. We now report the development of the FVII gene (F7) Variant Database (f7-
db.eahad.org). 
 
Materials and Methods 
Database Structure 
The database was built on a common architecture developed for blood coagulation variant databases, using a 
MySQL platform and HTML, CSS, JavaScript, Perl and PHP interface. The first EAHAD database using this architecture 
was for F9 variants (Rallapalli et al., 2013). The database is available at f7-db.eahad.org. The variant data in the 
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databases is shared with LOVD; databases.lovd.nl/shared/genes/F7, which is a freely available gene centred 
collection of DNA variant data and is part of the GEN2PHEN and Human Variome projects (Fokkema et al., 2011). 
 
Identification of variants 
Data was initially imported from the original MRC FVII mutation database (McVey et al., 2001) and the UMD-F7 
mutation database (umd.be/F7)(Beroud et al., 2005). Subsequently additional variants were identified in the 
published literature. All variants incorporated into the new database were verified for accuracy and HGVS 
nomenclature was generated and checked with Mutalyzer (mutalyzer.nl/). All data referring to individual cases with 
variants in the F7 database is pseudo-anonymized and no information is provided on the site that identifies 
individuals. 
 
Nomenclature 
It is particularly important in molecular genetic analysis that there is no confusion resulting from differences in 
variant nomenclature between laboratories/publications. Many coagulation genes were cloned and initially 
sequenced during the 1980s, prior to the introduction of standardised nomenclature. As a result, genes and proteins 
have their own idiosyncrasies of naming and numbering. This can lead to confusion in the laboratory, literature and 
diagnostic setting. To reduce confusion, an ISTH working group published recommendations that full adoption of 
standard gene names and of DNA and protein sequence variant numbering according to HGVS guidelines should be 
adopted for all genes/proteins in haemostasis (Goodeve et al., 2011). All variants described in the Factor VII gene 
(F7) variant database therefore conform to HGVS guidelines and are reported in relation to reference sequences. 
The longest transcript NM_000131.4 is used to describe DNA variants with the A of the ATG initiator methionine 
utilized as the sequence start point +1 and similarly the first methionine is numbered +1 in the protein reference 
NP_000121.1. This differs from legacy numbering of FVII protein amino acid variants where the signal peptide and 
propeptide were numbered negatively, and amino acid numbering started from the beginning of the mature protein. 
However, to aid comparison with previous variant descriptions, both HGVS and legacy numbering is provided for 
each variant. Variants are described using cDNA and protein reference sequences, however in future releases 
variants will also be described using a locus genomic reference (LRG) sequence. This description is currently available 
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from the Leiden Open Variation Database (LOVD; lovd.nl) to which we mirror all variants described in the EAHAD 
database. 
 
In silico analyses 
The database provides access to in silico analyses that may be useful in the prediction of variant pathogenicity, using 
open access software packages (Align-GVGD, PolyPhen-2, SIFT & PROVEAN). The minor allele frequency (MAF) from 
the Genome Aggregation Database (gnomAD; gnomad.broadinstitute.org) is also provided. Where a MAF is not 
presented this indicates that this variant has not been identified in the data set and is a rare variant or in a region 
that is not read to an adequate depth in the control datasets. The position of a missense variant can also be 
visualized if the variant appears in the molecular model based on the structure of active site inhibited FVIIa in 
complex with human soluble TF (Protein Data Bank: 2A2Q). Finally, the evolutionary conservation of the amino acid 
sequence of the protein at the variant residue in closely related species: chimpanzee, gorilla, gibbon, bushbaby and 
marmoset can be inspected. Further multiple sequence alignments from more distantly related species and multiple 
alignment of human vitamin K-dependent coagulation factor protease domains are also available from the AA 
Alignments tab. 
 
Database content 
A total of 728 individual cases with plasma FVII:C levels outwith the normal range, identified by in vitro functional 
coagulation assays, and variants identified in their F7 gene(s) are compiled in the FVII gene (F7) variant database (f7-
db.eahad.org). 221 unique variants have been identified in the cohort. The database allows simple searches of 
variants based on nucleotide or amino acid numbering (HGVS and legacy), variant type, or location within the gene. 
In addition, advanced search options allow further refinement of searches based on variant effect, protein domain 
and severity (where known). A search returns the unique variants at the selected position in the gene or protein as a 
list with links where appropriate to in-depth analysis of the variation and anonymized patient information. 
 
Mutational spectrum 
The majority of the F7 variants reported are small lesions including deletions (7.7%), duplications (1.8%), insertions 
(0.5%), indel rearrangements (1.8%) all smaller than 20 nucleotides with the exception of two large deletions; and 
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single nucleotide substitutions (88.2%) with the majority of these being missense variants (74.3%) (Figure 2A; f7-
db.eahad.org/statistics.html.php). F7 is located 2.8kb upstream of F10 and therefore large rearrangements often 
involve both genes leading to combined FVII and FX deficiency (Pavlova et al., 2015). 
 
Variants have been identified throughout the gene with 14 identified in the 5’ untranslated and flanking region, 184 
in exons and 23 in introns. Similarly, variants have been identified in the coding sequence for all the protein 
domains: signal peptide (9), propeptide (9), GLA (18), EGF1 (13), EGF2 (17), activation peptide (7) and protease (116) 
domains (Figure 3). The 66bp exon 2 is an alternatively used exon present in the longest reference transcript 
(NM_000131.4) but absent from the most abundant and physiologically relevant mRNA transcript (NM_019616.3). It 
encodes additional amino acids in the propeptide sequence. Only 2 variants are described in this exon, the 
synonymous c.66C>T p.(Gly22=) and the c.130G>A p.(Val44Ile) variant. The increased number identified in the 
protease domain reflects the relative size of the coding sequence and not a higher variant rate. 
Some sites however have multiple variants in a single codon (29 codons with 2 variants and 8 codons with 3 or more 
variants), for example p.Ala251 has 4 different amino acid substitutions associated with variants in both c.751G and 
c.752C. 
 
There are 195 single nucleotide substitutions: 144 missense, 15 nonsense, 4 silent (synonymous) within the coding 
sequence and an additional 10 within the 5’ flanking region located within transcription factor binding sites, 2 in the 
5’ untranslated region and 20 intronic. Tools for assessing the pathogenicity of these variants are discussed below 
but many missense variants are predicted to result in a variety of consequences including functional and misfolding 
defects. The variants in transcription factor binding sites have been extensively studied and shown to result in either 
increased or decreased transcription. The intronic variants are predicted to result in splice variants as a consequence 
of various mechanisms: 10 are located in the canonical “-1, +1, -2, +2” splice nucleotides, 4 in the critical intronic 
“+5” position, 2 are located at less conserved positions namely -11 and -12. In addition, a small 4 nucleotide-deletion 
within intron 8 (c.805+3_805+6del) and a synonymous variant located at the last nucleotide of exon 3 (c.291G>C or 
p.(Thr97=)) are also predicted to result in aberrant splicing (Millar et al., 2000; Pinotti et al., 1998). 
 
Impact of common variants known to modulate FVII levels 
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A number of common variants have been identified in F7 (Table 1). Some of these variants, which are in strong 
disequilibrium with each other, have been extensively studied in relation to FVII:C and antigen (FVII:Ag) levels. The 
F7 promoter haplotype [c.-401G>T, c.-325_-324insCCTATATCCT, c.-122T>C], and the missense variant c.1238G>A 
p.(Arg413Gln) are associated with decreased levels of FVII:C and FVII:Ag of approximately 30% and 23% respectively 
(Bernardi et al., 1996) in patients and confirmed by in vitro studies (Hunault, Arbini, Lopaciuk, Carew, & Bauer, 1997; 
Pollak, Hung, Godin, Overton, & High, 1996). In contrast, the rare c.-402A allele is associated with increased 
transcriptional activity (van 't Hooft et al., 1999) resulting in significantly higher FVII:C and FVII:Ag levels than 
individuals homozygous for the common c.-402G allele (Lindman, Pedersen, Arnesen, Hjerkinn, & Seljeflot, 2005). 
Intron 8 is the location of a VNTR repeat of 37bp with its own modulating effect. A quantitative analysis of 
transcripts indicated a parallel decrease of the VNTR repeat number and mRNA relative expression. Both 
c.795_805+26[8] and c.795_805+26[7] repeats showed higher values than the reference c. 795_805+26[6], whereas 
c.795_805+26[5] repeats showed lower values (Pinotti et al., 2000). The in vitro results were confirmed in genetic 
association studies for the c.795_805+26[7] allele contributing to a 17% variance of FVII:C levels (Bernardi et al., 
1996). 
 
The impact of the common variants on the combined expression of function FVII:C activity is complex as they may be 
either inherited in cis or trans with the rare variant being analyzed. Often it will not be possible to assign the linkage 
because family studies are usually not reported. Nevertheless, it may be possible to draw conclusions of the impact 
of the common variants when they are present in a homozygous state. To illustrate this point, 8 patients 
heterozygous for the p.(Ala304Val) missense variant but with various combinations of the p.(Arg413Gln) common 
variant were compared to each other. Four of them were homozygous for the p.(Arg413Gln) allele resulting in the 
p.[(Ala304Val); Arg413Gln)];[(Arg413Gln)] genotype whereas the remaining four were classified into the other 
possible combinations of genotypes: p.[(Ala304Val;Arg413Gln)];[(Arg413=)], p.[(Ala403Val;Arg413=)];[(Arg413=)] or 
p.[(Ala403Val;Arg413=)];[(Arg413Gln)] according to the provided pedigree (Alshinawi, Scerri, Galdies, Aquilina, & 
Felice, 1998). Interestingly, both p.[(Ala304Val;Arg413Gln)];[(Arg413Gln)] and p.[(Ala403Val;Arg413=)];[(Arg413Gln)]  
patients with no wild type allele remaining, displayed the lowest FVII:C levels ranging from 25 to 32% (Tamary et al., 
1996) whereas the p.[(Ala304Val;Arg413Gln)];[(Arg413=)] and p.[(Ala403Val;Arg413=)];[(Arg413=)] had the highest 
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FVII:C levels of 38-45% and 46% respectively. The location in cis or in trans of the modulating common variants will 
therefore be provided when available for future submissions to this database. 
 
Individual data 
In common with the other EAHAD coagulation factor databases, the F7 database stores and displays all cases 
reported regardless of how many individual reports of the identical genetic variant have been reported, allowing 
users to survey phenotypic variability among cases with the same genetic variant. Where appropriate additional 
variants within an individual case are reported, including the common F7 variants allowing analysis of combined 
genotypes of a rare variant and a common variant. It should be noted that in some cases the frequency of reporting 
variants is biased by extensive family studies or founder effects in certain ethnic groups, for example p.(Ala354Val) in 
North and North-East Europe (99 individuals) and p.(Ala304Val) in Jewish populations (38 individuals). It is possible 
to visualize/export the data either as a list of unique variants at the selected position, or as a multiple patient list 
showing all individuals with a particular variant at that position, allowing between-case comparisons to assess 
variant frequency and variability of presentation. Thus, despite the wide heterogeneity, 17 variants are highly 
frequent. Four missense variants are found more than 50 times, namely p.(Gln160Arg), p.(Ala304Val), p.(Ala354Val) 
combined with p.(Pro464Hisfs*32) and p.(Arg364Gln) (also known as FVII Padua). Five missense variants are found 
between 20 and 50 times and nine variants between 10 and 19 times (Figure 3). 
 
Impact of thromboplastin source for FVII:C measurement 
It is well-documented that some FVII protein variants display variations in the FVII:C measurement according to the 
species of the thromboplastin reagent (tissue factor; TF) that has been used to trigger the in vitro measurement. 
Historically bovine and rabbit sources were used before the introduction of recombinant human thromboplastin. 
The FVII:C value has therefore been recorded in the database with the species of the corresponding thromboplastin 
reagent where this information was available in the original report. Thirty-nine individuals were reported with FVII:C 
levels determined with thromboplastin of both human and rabbit origin. Seventeen displayed significant variations 
between FVII:C levels when measured with the different thromboplastins. The corresponding variants are: 
p.(Gly391Asp), p.(Arg364Gln), p.(Arg364Trp), p.(Arg337His), p.(Arg139Gln) (Matsushita, Kojima, Emi, Takahashi, & 
Saito, 1994; Mourey et al., 2014; O'Brien et al., 1991; Takamiya & Takeuchi, 1998; Zheng, Shurafa, & James, 1996). 
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Importantly, the impact of the residual FVII:C levels measured in vitro on the potential bleeding phenotype of the 
individual should only be considered when assayed with human thromboplastin. 
 
Clinical phenotype and genotype 
The database presents statistics and graphics on all the variants in the database by specific type of variant, by 
protein domain and by disease severity available from the Variants tab allowing users to analyze relationships 
between clinical phenotype and genotype. Mariani et al (Mariani et al., 2005) proposed a standard classification of 
clinical severity for FVII deficiency which we would encourage all reporting of FVII deficiency to use. However, the 
lack of a standard classification of the observed clinical phenotype prior to 2005 requires users to refer back to the 
original publication to ascertain the scheme used if the phenotypic severity is to be used in the interpretation of the 
pathogenicity of the variant. 
 
The 728 patients present a wide range of clinical phenotypes, from asymptomatic (34.6%; often identified in pre-
operative coagulation screening) to individuals suffering severe bleeds (21.2%) (Figure 2B). The large majority of the 
154 patients (92%) with severe bleeding tendency displayed FVII:C levels below 5%. Of those determined with 
human thromboplastin the majority displayed FVII:C levels below 2.9%. Genotypically, severe patients are either 
homozygous or compound heterozygous for nonsense, canonical splice site, frameshift, missense variants resulting 
in substitution of critical residues for the FVII function (namely, arginine residue at the proteolytic activation site 
(Arg212), the catalytic triad (Asp302), or residues involved in the disulfide bond (Cys195), between the light and 
heavy chains of the activated form of FVII), variants at transcription factor binding sites within the F7 promoter or 
variants predicted to dramatically alter the protein folding namely p.(Gln160Arg) or p.(Thr419Met). However, the 
converse was not always true. Of the 65 individuals homozygous for variants predicted to be pathogenic (Table 2) 
there were 27 reported not to have a severe bleeding tendency. Two asymptomatic patients were homozygous for 
the p.(Arg462*) nonsense variant occurring only 4 residues before the natural termination signal. The 4 residue-
carboxy-terminal-truncated protein has been reported to have increased specific activity and gain-of-function 
features (Branchini et al., 2012) explaining the observed asymptomatic phenotype. Conversely, it was unexpected 
that an individual homozygous for the consensus splice site c.572-1G>A was reported with only epistaxis at the age 
of three (Kwon, Yoo, Lee, Kim, & Kim, 2011) or an individual homozygous for the critical variant p.(Arg212Gln) 
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reportedly with a mild bleeding phenotype despite FVII:C levels of <1% and 4 other cases homozygous for this 
variant reported as having severe haemorrhagic phenotypes. As for other clotting factors deficiencies, homozygotes 
for frameshift variants displayed the largest clinical heterogeneity. One explanation could be a partial correction by 
ribosomal slippage and DNA replication/RNA transcription errors as suggested for F8 (Young et al., 1997). 
 
Assessing pathogenicity of F7 variants 
Variant classification is central to the utility of molecular genetic diagnostics in clinical practice, however, predicting 
whether gene variants are likely to be pathogenic may not be straightforward. The F7 variant database currently 
does not assign pathogenicity to an individual variant but rather provides access to a number of tools to allow 
assessment of the variant according to published guidelines that establish a framework for variant classification 
(Nykamp et al., 2017; Richards et al., 2015). In future releases the database will link directly to ClinVar 
(ncbi.nlm.nih.gov/clinvar) which is an open access database that reports curated information and likely 
pathogenicity on gene variants. EAHAD curators are working as co-chairs or members of relevant curation panels 
that input into ClinVar. 
Evidence for pathogenicity can be obtained from evaluation of variant frequencies from large population datasets; 
variant type; clinical observations; experimental studies and computational analyses. Each variant in the F7 database 
is assigned a variant ID and the variant ID view (Figure 4A) displays the cDNA change, the amino acid change, the 
type of variant (deletion, duplication, indel, insertion or point), the effect (frameshift, in-frame, intronic, missense, 
nonsense, promoter or silent), the location within the gene (untranslated region, flanking sequence, exon or intron) 
as well as within the protein (domain) and finally, the minor allele frequency (MAF) is obtained from the gnomAD 
database that calculates the frequency from 125,748 exomes and 15,708 genomes. 
 
The MAF value can provide strong evidence that a variant is benign or that it is sufficiently rare to be considered a 
candidate pathogenic variant. However, MAF values can sometimes be misleading. For example, two variants with 
high MAFs of 0.1419 and 0.1341 respectively are p.(His175=) and p.(Arg413Gln). The high frequency and variant type 
would lead to the assignment of p.(His175=) as non-pathogenic. Whereas p.(Arg413Gln) is a frequent missense 
variant associated with decreased levels of FVII and although not directly pathogenic it can contribute to the 
consequence of co-inherited variants. 
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In order to assess the clinical observations each variant is associated with the number of individuals reported, 
laboratory measurements of FVII:C (TF: unknown, human or rabbit) and FVII:Ag plasma levels, reported clinical 
severity as well as whether the variant is homozygous or heterozygous. Additional variants identified in each 
individual are also collated. For each missense variant computational analysis using in silico tools (Align-GVGD, 
Polyphen-2, SIFT and PROVEAN) to predict the likely impact on the resultant protein are provided. It is also possible 
to visualize the potential structural implications by viewing the variant in a molecular model based on the X-ray 
crystal structure of the TF-FVIIa complex or in multiple sequence alignments of the FVII amino acid sequence across 
primates or the serine protease domains of the human vitamin K dependent coagulation factors (FVII, FIX, FX, 
Protein C) (Figure 4B). 
 
Conclusions 
DNA sequence analysis (either classical Sanger DNA sequencing or more commonly exome/complete genome 
sequencing) is now standard in the characterisation of inherited disease. Most variants identified are single 
nucleotide variants and predicting the pathogenicity of these variants may be difficult. Deficiency of FVII is an 
autosomal recessive bleeding disorder with a highly variable phenotype, ranging from lethal to mild to even 
asymptomatic. The correlation between residual clotting activity and the clinical severity of associated bleeding is 
less clear than in the more common inherited bleeding disorders haemophilia A and B. This is further complicated by 
the use of non-human TF as the trigger for functional coagulation assays resulting in discrepant in vitro results that 
are inconsistent with FVII:C assays performed using human TF and the bleeding phenotype of the individual 
concerned. This has often resulted in the identification of individuals with variants in their F7 gene who are 
asymptomatic. The co-inheritance of common variants that can affect the expression levels of plasma FVII:Ag further 
complicates the analysis of potential pathogenicity. 
 
An integrated comprehensive analysis is therefore key to understanding the consequence of a variant. In the F7 
variant database for any variant it is possible to obtain the description at cDNA and amino acid (both HGVS and 
legacy) levels, the type of variant, and the location of the variant within the gene and protein. Each individual 
reported to carry the variant is displayed along with the reported clinical severity, whether the individual is hetero- 
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or homozygous for the variant and any other variants identified in each individual. The generation and maintenance 
of an online open access database by a team of specialised curators that incorporates all described variants in F7 and 
their associated properties and functional activities in addition to in depth computational analysis of the 
consequence of the variant significantly aids the assessment of pathogenicity. 
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Figure Legends 
Figure 1: Factor VII structure and function 
A. Schematic of TF-FVIIa initiated thrombin generation. The network includes elements of coagulation initiation 
via TF-FVIIa interaction, amplification via FIXa-FVIIIa and FXa-FVa complexes leading to thrombin generation 
and formation of a fibrin clot. Positive feedback loops are represented by dashed lines coloured red and 
inhibition of the TF-FVIIa-FXa complex by tissue factor pathway inhibitor by dashed blue line. 
B. Molecular model of Factor VIIa derived from the complex between active site inhibited FVIIa and the 
extracellular domain of tissue factor (Protein Databank: 1DAN). FVIIa protein chain is represented by a 
ribbon. The active site inhibitor is shown in ball and stick. Calcium ions are represented by green spheres. 
EGF, epidermal growth factor; GLA, γ-carboxylated. 
 
Figure 2: Pie charts indicating the variant type and clinical severity 
A. Variant type of the 221 unique variants in the database 
B. Classification of the 728 individual cases in the database according to clinical severity 
 
Figure 3: Frequency and location of the 221 unique variants 
The number of individuals reported with variants in the amino acid sequence of the protein is plotted. The 
correspondence of the primary amino acid sequence with the domain structure of the protein is shown below with 
the number and percentage of unique variants reported in each domain. 
 
Figure 4: Representative screen shots of the EAHAD Factor VII Gene (F7) variant database 
A. An example of a Variant ID page; shown for F7:p.(Arg139Gln). The molecular details of the variant are listed. 
All cases reported to carry the variant on at least one allele with links to the individual case details and 
reference. 
B. An example of an In depth variant analysis view; shown for F7:p.(Gln160Arg). Substitution analysis scores are 
provided for Grantham (Align-GVGD), PolyPhen-2, SIFT and PROVEAN. The location of the missense variant is 
indicated by a red sphere in a molecular model derived for the X-ray structure of the TF-FVIIa complex. 
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Table 1: F7 Common Variants 
ID Type Effect Location cDNA change Amino acid 
 change 
MAF Legacy  
Nomenclature 
rs510317 Point Promoter Flanking (5') c.-402G>A  0.2326 NA 
rs510335 Point Promoter Flanking (5') c.-401G>T  0.2041 NA 
rs5742910 Insertion Promoter Flanking (5') c.-325_-324insCCTATATCCT  0.23 WT=A1: Var=A2 
rs561241 Point Promoter Flanking (5') c.-122T>C  0.1436 WT=P1: Var=P2 
rs6039 Point Intronic Intron (1) c.64+9G>A  0.1403992 G73A (DNA numbering) 
WT=G1: Var=G2 
rs6042 Point Silent Exon (6) c.525C>T p.(His175=) (H115=) 0.1345885 WT=H1 (or C1): Var=H2 (or C2) 
VNTR[8] Indel Intronic Exon (8) c.795_805+26[8]   NA 
VNTR[5] Indel Intronic Exon (8) c.795_805+26[5]   NA 
VNTR[7] Indel Intronic Exon (8) c.795_805+26[7]  0.31 Var=a (7) or h7 
rs6041 Point Intronic Intron (8) c.806-20G>A  0.1274271 WT=I1: Var=I2 
rs6046 Point Missense Exon (9) c.1238G>A p.(Arg413Gln) (R353Q) 0.1265056 WT=M1: Var=M2 
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Table 2: Characteristics of the 65 cases homozygous for a pathogenic variant 
 Variant* Phenotype Number of cases 
      
Type cDNA numbering Protein numbering FVII :C (FVII :Ag) Bleeding tendency  
Nonsense c.335C>G 
c.396C>A 
c.859C>T 
c.1324C>T 
c.1384C>T 
p.(Ser112*) 
p.(Cys132*) 
p.(Gln287*) 
p.(Gln442*) 
p.(Arg462*) 
<1 (ND) 
<1 (ND) 
<1 (ND) 
<1 (ND) 
2-3 (<1-ND) 
Severe 
Severe 
Severe 
Severe 
Asymptomatic 
1 
1 
3 
1 
2 
Consensus splice site c.291G>C 
c.291+1G>A 
c.291+1G>C 
c.292-2A>G 
c.430+1G>A 
c.572-1G>A 
 
c.681+1G>T 
p.(Thr97=) 
NA 
NA 
NA 
NA 
NA 
 
NA 
<1(19) 
<1 (<1) 
<1(<1) 
ND 
<1 (4 for one patient) 
<5 (ND) 
 
<1 (ND) 
Severe 
Severe 
Severe 
Severe 
Severe 
1 Severe 
1 Mild 
Severe 
1 
1 
2 
3 
1 
2 
 
1 
Frameshift c.16delC 
 
c.27_28delCT 
 
c.1061C>T 
+c.1391delC 
 
 
 
p.(Leu6Serfs*41) 
 
p.(Cys10Profs*16) 
 
p.(Ala354Val) + p.(Pro464Hisfs*32) 
 
 
 
<1 
 
<1 
 
<2 (<2-3) 
 
 
 
1 Severe 
1 Moderate 
2 Severe 
2 Mild 
5 Severe, 
15 Moderate 
1 Mild 
4 Asymptomatic 
2 
 
4 
 
25 
 
 
 
Missense variants resulting in 
substitution of  
critical residues 
c.583T>C 
c.635G>A 
 
c.635G>A + c.416G>A 
c.904G>A 
p.(Cys195Arg) 
p.(Arg212Gln) 
 
p.(Arg212Gln) + p.(Arg139Gln) 
p.(Asp302Asn) 
1 (<5) 
<1 (>75) 
 
<1 (>75) 
<1 (9) 
Severe 
4 Severe 
1 Mild 
Severe 
Severe 
2 
5 
 
1 
2 
Promoter transcription  
factor binding site  
c.-94C>G 
c.-65G>C 
c.-61T>G 
c.-60_-59delTT 
c.-55C>T 
 
NA 
NA 
NA 
NA 
NA 
<1 (<1) 
<1 (<1) 
<1 (<1) 
ND 
<1 (<1) 
 
Severe 
Severe 
Severe 
Severe 
Severe 
1 
1 
1 
1 
1 
 
*The variants classified as pathogenic are: nonsense, canonical splice site, frameshift, missense variants resulting in 
substitution of critical residues for FVII function namely, residues at the Arg212-Ile213 bond for proteolytic 
activation, at the catalytic site (His253, Asp302, Ser404), or residues involved in the unique disulfide bond between 
the light and heavy chains of the activated form of FVII (Cys195, Cys322), or variants at transcription factor binding 
sites within the F7 promoter (HNF4 and Sp1). 
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